OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
YSPS58

YSP Southeast Asia Holding Bhd

PharmaceuticalsVerified

YSP Southeast Asia Holding Bhd maintains a strong liquidity position, with a current ratio of 5.27 and cash and equivalents amounting to MYR 148.1 million, which is significantly higher than the industry median. The company's debt-to-equity ratio of 0.12 indicates a conservative capital structure, with long-term debt at MYR 50.8 million compared to total equity of MYR 417.9 million. Profitability metrics show a return on equity (ROE) of 5.99% and a return on assets (ROA) of 4.63%, which are in line with the industry's preferred metrics. The company's operating income of MYR 38.2 million and net income of MYR 25.0 million reflect a healthy margin, although gross profit of MYR 161.1 million suggests room for improvement in cost management. The company's revenue is distributed across three segments: Manufacturing, Trading, and Investment Holding. The Trading segment is the largest contributor, with a significant portion of revenue derived from the ASEAN region. The company's geographic exposure is concentrated in ASEAN, the Middle East, Africa, Australia, and New Zealand, with no significant diversification beyond these regions. Looking ahead, the company is projected to maintain a stable growth trajectory, with revenue expected to remain consistent in the current fiscal year and potentially increase in the next fiscal year. The company's capital expenditure of MYR -3.5 million indicates a focus on maintaining rather than expanding its current operations. Risk factors for the company are currently low, with no immediate liquidity or dilution flags detected. The company's low debt levels and strong cash reserves mitigate financial risk. However, the company's reliance on the pharmaceutical sector exposes it to regulatory and market volatility, which could impact future performance. Recent events, including filings and transcripts, have not indicated any significant changes in the company's operations or strategic direction. The company's ESG governance score of 68.8 and social score of 43.0 suggest a moderate level of commitment to environmental, social, and governance (ESG) practices.

30-day price · YSPS+0.04 (+1.9%)
Low$2.04High$2.13Close$2.13As of17 May, 00:00 UTC
Profile
CompanyYSP Southeast Asia Holding Bhd
TickerYSPS.KL
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. YSP Southeast Asia Holding Bhd is a Malaysia-based healthcare company engaged in the trading and manufacturing of pharmaceutical products, particularly generic drugs, and operates in the ASEAN, Middle East, Africa, Australia, and New Zealand markets.

Classification. The company is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry with a confidence level of 0.92.

YSP Southeast Asia Holding Bhd maintains a strong liquidity position, with a current ratio of 5.27 and cash and equivalents amounting to MYR 148.1 million, which is significantly higher than the industry median. The company's debt-to-equity ratio of 0.12 indicates a conservative capital structure, with long-term debt at MYR 50.8 million compared to total equity of MYR 417.9 million. Profitability metrics show a return on equity (ROE) of 5.99% and a return on assets (ROA) of 4.63%, which are in line with the industry's preferred metrics. The company's operating income of MYR 38.2 million and net income of MYR 25.0 million reflect a healthy margin, although gross profit of MYR 161.1 million suggests room for improvement in cost management. The company's revenue is distributed across three segments: Manufacturing, Trading, and Investment Holding. The Trading segment is the largest contributor, with a significant portion of revenue derived from the ASEAN region. The company's geographic exposure is concentrated in ASEAN, the Middle East, Africa, Australia, and New Zealand, with no significant diversification beyond these regions. Looking ahead, the company is projected to maintain a stable growth trajectory, with revenue expected to remain consistent in the current fiscal year and potentially increase in the next fiscal year. The company's capital expenditure of MYR -3.5 million indicates a focus on maintaining rather than expanding its current operations. Risk factors for the company are currently low, with no immediate liquidity or dilution flags detected. The company's low debt levels and strong cash reserves mitigate financial risk. However, the company's reliance on the pharmaceutical sector exposes it to regulatory and market volatility, which could impact future performance. Recent events, including filings and transcripts, have not indicated any significant changes in the company's operations or strategic direction. The company's ESG governance score of 68.8 and social score of 43.0 suggest a moderate level of commitment to environmental, social, and governance (ESG) practices.
Key takeaways
  • YSP Southeast Asia Holding Bhd has a strong liquidity position with a current ratio of 5.27 and significant cash reserves.
  • The company's conservative capital structure, with a debt-to-equity ratio of 0.12, reduces financial risk.
  • Profitability metrics, including ROE of 5.99% and ROA of 4.63%, are in line with industry standards.
  • The company's revenue is concentrated in the Trading segment and the ASEAN region, which may limit diversification benefits.
  • The company is projected to maintain stable growth with no significant capital expenditure planned.
  • ESG governance practices are moderate, with a governance score of 68.8 and a social score of 43.0.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyMYR
Revenue$365.1M
Gross profit$161.1M
Operating income$38.2M
Net income$25.0M
R&D
SG&A
D&A
SBC
Operating cash flow$55.0M
CapEx-$3.5M
Free cash flow$17.4M
Total assets$541.1M
Total liabilities$123.2M
Total equity$417.9M
Cash & equivalents$148.1M
Long-term debt$50.8M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$417.9M
Net cash$97.3M
Current ratio5.3
Debt/Equity0.1
ROA4.6%
ROE6.0%
Cash conversion2.2%
CapEx/Revenue-0.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
MetricYSPSActivity
Op margin10.5%-2.9% medp25 -218.9% · p75 9.6%top quartile
Net margin6.9%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin44.1%47.8% medp25 27.6% · p75 68.9%below median
CapEx / revenue-0.9%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity12.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Observations
IR observations
market data ESG controversies score100.0
market data ESG governance pillar68.8
market data ESG social pillar43.0
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 06:38 UTC#fde96bc0
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 06:41 UTCJob: 62ef5bec